ABOUT THIS EPISODE
Recce Pharmaceuticals Ltd managing director and CEO James Graham talked with Proactive about the company’s exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for RECCE® 327 topical gel (R327G) in Australia and New Zealand.
Graham described the agreement as a significant step for Recce Pharmaceuticals, highlighting Arrotex’s pharmaceutical sales, marketing, distribution and market-access capabilities across Australia and New Zealand. He said the partnership allows each company to focus on its respective strengths as R327G progresses through clinical development.
Graham also discussed Arrotex’s reach within Australia’s Pharmaceutical Benefits Scheme and across hospitals, clinics and pharmacies, describing the company as a strong commercialisation partner for R327G.
Graham discussed clinical work underway in Indonesia as well as the company’s Australian Phase 3 study, with Australian data expected to be an important part of the regulatory pathway.
He said the Indonesian study was already demonstrating what he described as a strong efficacy signal while maintaining an excellent safety profile. The Australian study remains underway, with further clinical data expected as the program advances.
Looking ahead, Graham identified potential clinical data readouts, regulatory submissions and additional licensing opportunities in surrounding markets as important milestones for R327G.
Visit Proactive’s YouTube channel for more interviews and updates from listed companies and industry leaders. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future Proactive content.
#ReccePharmaceuticals #RCE #RECEF #R327G #RECCE327 #ArrotexPharmaceuticals #DiabeticFootInfection #DFI #Phase3 #ClinicalTrials #Biotech #Pharmaceuticals #AntiInfectives #DrugDevelopment #Healthcare #ASX #Australia #NewZealand
Graham described the agreement as a significant step for Recce Pharmaceuticals, highlighting Arrotex’s pharmaceutical sales, marketing, distribution and market-access capabilities across Australia and New Zealand. He said the partnership allows each company to focus on its respective strengths as R327G progresses through clinical development.
Graham also discussed Arrotex’s reach within Australia’s Pharmaceutical Benefits Scheme and across hospitals, clinics and pharmacies, describing the company as a strong commercialisation partner for R327G.
Graham discussed clinical work underway in Indonesia as well as the company’s Australian Phase 3 study, with Australian data expected to be an important part of the regulatory pathway.
He said the Indonesian study was already demonstrating what he described as a strong efficacy signal while maintaining an excellent safety profile. The Australian study remains underway, with further clinical data expected as the program advances.
Looking ahead, Graham identified potential clinical data readouts, regulatory submissions and additional licensing opportunities in surrounding markets as important milestones for R327G.
Visit Proactive’s YouTube channel for more interviews and updates from listed companies and industry leaders. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future Proactive content.
#ReccePharmaceuticals #RCE #RECEF #R327G #RECCE327 #ArrotexPharmaceuticals #DiabeticFootInfection #DFI #Phase3 #ClinicalTrials #Biotech #Pharmaceuticals #AntiInfectives #DrugDevelopment #Healthcare #ASX #Australia #NewZealand
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Proactive - Interviews for investors.
OTHER EPISODES IN THIS PODCAST
OTC Markets Group Head of APAC, International Corporate Services Stephen Shipley talked with Proactive about the company’s strategy for expanding its presence across the Asia-Pacific region and helping international companies improve access to US investors.
Speaking from Sydney during IMARC, Shipl…
S&U PLC (LSE:SUS) chairman Anthony Coombs spoke with Proactive's Stephen Gunnion about the group’s new £600 million funding facilities, which replace £330 million of existing arrangements at improved rates and support its next phase of growth.
Coombs described the deal as transformational, giv…
Cascade Copper CEO Jeff Ackert joined Steve Darling from Proactive to discuss recent drilling results at the company’s Centerfire project in Ontario, plans for a second phase of exploration and preparations for drilling at the Copper Plateau project in British Columbia.
Ackert explained that Casca…
Midnight Sun Mining Corp Vice President of Business Development Adrian O’Brien joined Steve Darling from Proactive to provide an update on ongoing drilling at the company’s Dumbwa copper deposit in Zambia, where recent results are pointing to a significant expansion of the mineralized system in the…
Hive Digital Technologies Executive Chairman Frank Holmes Steve Darling from Proactive to discuss a major financing agreement for the company’s subsidiary, BUZZ High Performance Computing (BUZZ HPC), which has secured an approximately $129 million credit facility to fund advanced AI computing infra…
Disclaimer: The podcast and artwork embedded on this page are from Proactive, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
